Abstract

Treating Inner Ear Disorders with Intratympanic Drug Administration

Author(s): McElhiney Linda F

Issue: Jul/Aug 2011 - Volume 15, Number 4

Page(s): 302-307

Download in electronic PDF format for $75
  • Treating Inner Ear Disorders with Intratympanic Drug Administration Page 1
  • Treating Inner Ear Disorders with Intratympanic Drug Administration Page 2
  • Treating Inner Ear Disorders with Intratympanic Drug Administration Page 3
  • Treating Inner Ear Disorders with Intratympanic Drug Administration Page 4
  • Treating Inner Ear Disorders with Intratympanic Drug Administration Page 5
  • Treating Inner Ear Disorders with Intratympanic Drug Administration Page 6

Abstract

Inner ear diseases are often treated in outpatient clinic settings that do not have United States Pharmacopeia Chapter <797>-compliant facilities to prepare the medications used for intratympanic administration. Compounding pharmacists can provide a valuable service to otolaryngologists by preparing these compounds in a sterile environment and hopefully reduce the chance of infection for these patients. This article focuses on the use and compounding of intratympanic dexamethasone to treat sudden sensorineural hearing loss and the use of intratympanic buffered gentamicin to treat the incapacitating vertigo in Ménière’s disease.

Related Keywords

  • inner ear disorders
  • hearing disorders
  • presbycusis
  • age-related hearing loss
  • sudden sensorineural hearing loss
  • ototoxic drugs
  • Meniere disease
  • benign positional vertigo
  • labyrinthitis
  • steroids
  • anti-inflammatory agents
  • intratympanic administration
  • dexamethasone
  • buffered gentamicin
  • formulations
  • drug delivery
  • hydrogels
  • tympanic membrane
  • ear drum
  • ear canal
  • myringotomy
  • ventilation tubes

Related Categories

  • EAR NOSE THROAT
  • FORMULATIONS
  • ALLERGY/IMMUNOLOGY/INFLAMMATION
  • DOSAGE FORMS/DRUG CARRIERS

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy		 Title/Author
(Click for Abstract / Details / Purchase)
Jul/Aug 2011
Pg. 302-307
Treating Inner Ear Disorders with Intratympanic Drug Administration
Author(s): McElhiney Linda F
Jan/Feb 2004
Pg. 46-48
Basics of Compounding for Disorders of the External Ear
Author(s): Allen Loyd V Jr
May/Jun 2003
Pg. 170-174
Five Compounds for Treating Diabetes-Related Conditions
Author(s): Meece Jerry
Sep/Oct 2009
Pg. 386-389
Skin Disorders in Horses; Case Report: Tripelennamine in the Treatment of Skin Disorders in Horses
Author(s): Williams LaVonn A, Fokken Dawn
Mar/Apr 2018
Pg. 92
PreScription: Drug Quality and Security Act Implementation Subcommittee Hearing
Author(s): Allen Loyd V Jr
May/Jun 2003
Pg. 188-191
Treating Canine Hepatic Disease
Author(s): Davidson Gigi S
May/Jun 2010
Pg. 182-192
Compounded Analgesic Therapy for Disorders of Movement: Arthritis, Neuropathic Pain, and Postpolio Syndrome
Author(s): Brown Scott, Erickson Brian, Muller George, Bryant-Snure Susan J, Mestayer Richard F III
Jan/Feb 2008
Pg. 8-14
Intravitreal Bevacizumab for Choroidal Neovascularization in Age-Related Macular Degeneration
Author(s): Dib Jean G, Abdulmohsin Saud
Jul/Aug 2003
Pg. 288-291
Basics of Compounding for Raynaud's Disease
Author(s): Glasnapp Andrew
Sep/Oct 2017
Pg. 356
PreScription: 2017 Pharmacy Compounding Issues: The U.S. Food and Drug Administration, Harzardous Drugs, and Wasted Drugs
Author(s): Allen Loyd V Jr
Mar/Apr 1997
Pg. 87-89
Attention Deficit Hyperactivity Disorder
Author(s): Allen Loyd V Jr
Jul/Aug 1998
Pg. 277
Swim Ear Drops ( "In Your Ear" )
Author(s): Nelson James L
Mar/Apr 2010
Pg. 171-173
Low Dose Naltrexone: Side Effects and Efficacy in Gastrointestinal Disorders
Author(s): Ploesser Jennifer, Weinstock Leonard B, Thomas Erin
Jan/Feb 2018
Pg. 57
Sodium Citrate 9% Nasal Spray for Olfactory Disorders
Author(s): Allen Loyd V Jr
Jan/Feb 2020
Pg. 30-36
Quality Control: Personal Protective Equipment for Use When Handling Hazardous Drugs
Author(s): Dillon L R
Jul/Aug 2016
Pg. 351
View Sample
Discrepancies in the Law and the U.S. Food and Drug Administration Pharmacy Compounding Compliance Policy Guidelines
Author(s): Allen Loyd V Jr
Jan/Feb 2001
Pg. 21-22
Methylphenidate in the Treatment of Attention Deficit Disorders
Author(s): Tenreiro Kim
Jul/Aug 2005
Pg. 275-278
Compounding for Endocrine Disorders in Adult Patients
Author(s): Grajeda Betty Jo, Vail Jane
Jul/Aug 2025
Pg. 267-278
Legal Challenges to Compounding Drugs for Weight Loss
Author(s): Combs Blinn E, Howard Brad
Mar/Apr 2018
Pg. 108-121
Personalized Medicine and Customized Drug Delivery Systems: The New Trend of Drug Delivery and Disease Management
Author(s): Soni Abhishek, Gowthamarajan Kuppusamy, Radhakrishnan Arun